

## Special Issue

# Advanced Ovarian Cancer (2nd Edition)

### Message from the Guest Editor

In the past decade, there has been significant progress in the evaluation and treatment of advanced ovarian cancer in addition to a combination of debulking surgery and systemic chemotherapy, such as homologous recombination deficiency evaluation, hyperthermic intraperitoneal chemotherapy, anti-vascular endothelial growth factor therapy, poly ADP-ribose polymerase inhibitor, and even immune checkpoint inhibitor. However, the prognosis of a significant portion of patients with advanced ovarian cancer remains poor. Thus, intensive study is needed to determine the optimal evaluation and treatment strategies. We welcome submissions in advanced or recurrent ovarian cancer that cover any relevant topic in the areas of risk assessment and stratification, and medical and surgical management strategies.

---

### Guest Editor

Prof. Sheng-Mou Hsiao

1. Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei 220216, Taiwan
2. Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan
3. Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei 100226, Taiwan

---

### Deadline for manuscript submissions

closed (31 December 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/233913](https://mdpi.com/si/233913)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)